The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

BIOCHEMICAL GENETICS, published by Springer/Plenum Publishers, is a prominent journal in the fields of biochemistry, genetics, and molecular biology, with a substantial impact on the scientific community since its inception in 1967. The journal holds a significant position within various academic quartiles, ranking Q2 in Ecology, Evolution, Behavior and Systematics, and Q3 in Biochemistry, Genetics, and Medicine (miscellaneous), among others, demonstrating its diverse and interdisciplinary reach. With an ISSN of 0006-2928 and an E-ISSN of 1573-4927, it is recognized for contributing critical research insights and methodologies that drive the fields of biochemical genetics forward. Although it is not an Open Access journal, it provides vital access options and resources for researchers globally, facilitating the dissemination of knowledge across institutions. Positioned within the competitive landscape of Scopus rankings, it maintains respectable standings across its focused areas, making it an invaluable resource for researchers, professionals, and students seeking to deepen their understanding of genetic mechanisms and biochemical processes.

ACTA BIOCHIMICA POLONICA (ISSN: 0001-527X, E-ISSN: 1734-154X) is a distinguished journal published by the ACTA BIOCHIMICA POLONICA in Poland, with a rich history dating back to 1955. As a prominent platform for disseminating research, it currently holds a Category Quartile of Q3 in the fields of Biochemistry, Genetics, and Molecular Biology, reflecting its commitment to advancing knowledge in these critical areas. This journal is indexed in Scopus, ranking 124 out of 221, placing it in the 44th percentile among general biochemistry, genetics, and molecular biology journals. Although it does not operate under an open-access model, ACTA BIOCHIMICA POLONICA remains a vital resource for researchers, professionals, and students seeking to delve into the latest developments and discoveries in biochemistry and molecular biology. Its strategic focus on contemporary topics ensures that it plays an essential role in shaping future scientific inquiries and fostering collaboration across various disciplines.

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.